首页|脊髓性肌萎缩症疾病修正治疗真实世界研究进展

脊髓性肌萎缩症疾病修正治疗真实世界研究进展

扫码查看
脊髓性肌萎缩症(SMA)是一种遗传性的神经肌肉疾病,会导致患者出现渐进式的肌无力和肌萎缩,严重者甚至死亡.近年来,SMA修正治疗药物的出现,极大地改善了患者的临床症状及提升了患者的生活质量.此类药物的长期有效性和安全性,以及对疗效的各种影响因素尚未明确,需进一步监测和研究.本文通过对SMA修正治疗药物的真实世界有效性、安全性研究进行综述,以期对SMA精准化及个体化治疗提供一些新启发及思考.
Advances in real-world research on disease-modifying treatments for spinal muscular atrophy
Spinal muscular atrophy(SMA)is a genetic neuromuscular disorder that leads to muscle weakness,atrophy,and which can lead to death in severe cases.Recently,therapeutic drugs that can modify SMA have emerged and have significantly improved the clinical symptoms and the quality of life of patients.However,the long-term efficacy and safety of these drugs are not yet established,and various confounding factors affecting drug efficacy need further analysis and study.This article reviews the real-world efficacy and safety studies of drugs for SMA modification drugs,intending to provide some new inspirations and thaughts for the precision and individualized treatment of SMA.

spinal muscular atrophydisease-modifying therapyefficacysafetyreal-world research

吴献、刘艳、刘昕竹、黄晓会、马婧、徐阿晶、幸小东、蒋文高、张健

展开 >

上海交通大学医学院附属新华医院(上海 200092)

重庆医科大学药学院(重庆 400016)

脊髓性肌萎缩症 疾病修正治疗 有效性 安全性 真实世界研究

2025

临床儿科杂志
上海市儿科医学研究所 上海交通大学医学院附属新华医院

临床儿科杂志

北大核心
影响因子:1.486
ISSN:1000-3606
年,卷(期):2025.43(1)